MedTrace Logo

Determining Lipid Content in Stool After Alpha-cyclodextrin

NCT03002168 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-11-17

No results posted yet for this study

Summary

The Investigator hypothesizes that the currently used dose of dietary ingredient alpha-cyclodextrin (α-CD) will result in greater loss of dietary fat in the stool compared with placebo. The proposed studies will address the degree to which α-CD increases dietary fat loss.

The Investigator will conduct the study and analyze the samples at Mayo Clinic in Rochester, Minnesota.

Conditions

  • Healthy Participants

Interventions

DIETARY_SUPPLEMENT

Alpha-cyclodextrin

Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.

DIETARY_SUPPLEMENT

Placebo

Placebo tablets identical in appearance to the active comparator

RADIATION

Triolein radiolabeled with 100 microcuries of 3^Hydrogen

A MicroCurie (µCi) is a measure of radioactivity.

RADIATION

Tripalmitin radiolabeled with 20 microcuries of 14^Carbon

A MicroCurie (µCi) is a measure of radioactivity.

Sponsors & Collaborators

  • SFI Research

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Michael D Jensen, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-20
Primary Completion
2017-06-05
Completion
2017-06-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03002168 on ClinicalTrials.gov